{"schema_version":"secwatch.filing_event.v1","accession":"0001790340-26-000040","form_type":"8-K","ticker":"IMRX","cik":"0001790340","company_name":"Immuneering Corp","filed_at":"2026-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.192929+00:00","generated_at":"2026-05-15T18:51:09.697041+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Immuneering: FY2025 net loss $56M, cash $217M, 64% OS at 12 months in pancreatic cancer","bullets":["Net loss for FY2025 was $56.0M ($1.27/share), down from $61.0M ($2.04/share) in 2024.","Cash and marketable securities $217.0M as of Dec 31, 2025, with anticipated runway into 2029.","Phase 2a pancreatic cancer data: 64% OS at 12 months for atebimetinib + mGnP, above standard of care 35%.","Pivotal Phase 3 MAPKeeper 301 on track to dose first patient mid-2026; FDA and EMA alignment secured.","Plan to dose first patient in Phase 2 trial of atebimetinib + Libtayo in RAS-mutant NSCLC in 2H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001790340-26-000040","json":"https://secwatch.observer/filing/0001790340-26-000040.json","markdown":"https://secwatch.observer/filing/0001790340-26-000040.md","text":"https://secwatch.observer/filing/0001790340-26-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000040/0001790340-26-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1790340/000179034026000040/imrx-20260306.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T18:51:09.697041+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}